The present Competitive Intelligence Report about EGF-R agonists and antagonists provides a competitor evaluation in the field of epidermal growth factor receptor (EGF-R; ErbB1) targeting molecules for wound healing or treatment of cancer as of September 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The human epidermal growth factor receptor (HER) family members include EGFR (erbB1), HER2/neu (erbB2), HER3 (erbB3), and HER4 (erbB4) that are structurally related, and all except HER3 contain intracellular tyrosine kinase (tk) domain. All of the HER members, except HER2, bind to extracellular ligands

EGFR, a valid target in many epithelial malignancies, is a transmembrane protein with an extracellular ligand binding domain joined to an intracellular tyrosine kinase domain. Activation of EGFR induces a cascade of downstream signaling through several pathways, such as mitogenac tivated protein kinase (MAPK) and PI3-kinase / Akt/mTOR, resulting in cellular proliferation, differentiation, survival, motility, adhesion, and repair. EGFR is overexpressed or abnormally activated in several epithelial malignancies. Several antibodies targeting EGF-R and small molecules inhibiting the EGF-R tyrosine kinase have been approved and are used for treatment of colorectal cancer, squamous cell cancer of the head & neck or pancreatic cancer, respectively. EGF-R targeting therapeutics achieved 2008 sales of US$ 3.35 bln.

The pipeline of novel EGF-R targeting molecules is rather full and includes novel antibody as well as vaccine approaches and small molecules with a broader inhibition profile. At least six next generation antibodies against EGF-R are already in clinical development and more than ten biologics are preclinical R&D including dual target antibodies or vaccines. The small molecule pipeline is focused on dual EGF-R and Her2 as well as pan-Her tk inhibitors, but also includes multi-target EGF-R tk inhibitors.

The report includes a compilation of current active projects in research and development of molecules targeting the EGF receptor. In addition, the report lists company-specific R&D pipelines of EGF-R targeting small molecules, antibodies, proteins, cells and vaccines. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.
  

Index

• 2008 Sales of EGF-R Antagonists
• EGF-R Agonists
• Erbitux Pipeline
• Biologics as EGF-R Antagonists
• Selective EGF Receptor Antagonists
• Dual EGF-R and Her2 Receptor Antagonists
• Pan-ErbB (pan-Her) Receptor Antagonists
• Multi-Target EGF-R Antagonists
• Corporate EGF-R Agonist and Antagonist R&D Pipelines
• About La Merie

Corporate EGF-R Agonist and Antagonist R&D Pipelines

• Abbott
• Ambit Biosciences
• Amgen
• Array BioPharma
• AstraZeneca
• Attenuon
• Aveo Pharmaceuticals
• Avila Therapeutics
• Bharat Biotech International
• Biocon
• Boehringer Ingelheim
• Bristol-Myers Squibb (BMD)
• Celldex Therapeutics
• Chugai
• Curis
• Daewoong Pharmaceutical Co.
• Daiichi Sankyo
• DxS
• Eli Lilly
• Genmab
• GlaxoSmithKline (GSK)
• GlobeImmune
• Hana Biosciences
• InNexus Biotechnology
• ISU Abxis
• Jennerex Biotherapeutics
• Life Science Pharmaceuticals
• Med Discovery
• Medarex
• Merck Serono
• Micromet
• Oncalis
• Oncoscience
• Osi Pharmaceuticals
• Pfizer
• Roche (& Genentech)
• Scancell
• Shantha Biotechnics
• Shionogi
• Symphogen
• Takeda Pharmaceutical Co.
• Transition Therapeutics
• Uni-Bio Science Group
• Xencor
• YM Biosciences
• Zenotech Laboratories
• ZymoGenetics

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Pages: 66
Release Date: September of 2009
Format: PDF
Product Code: LMCA0050